Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RIAZ BABER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1740365808
CMS profile
169404
Location
NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$17.48

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $17.48 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
LivaNova USA, Inc. $17.48 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RIAZ BABER

NPI 1740365808 · CMS profile ID 169404

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
RIAZ BABER, NPI 1740365808, CMS profile ID 169404, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $17.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LivaNova USA, Inc. $17.4810/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 711985543 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $17.48 1
PY2021 $25.10 1
PY2022 $90.37 4
PY2023 $52.86 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $341,122.24 185
PY2024 Principal investigator $389,598.32 164
PY2023 Recipient $20,894.00 17
PY2023 Principal investigator $262,289.24 63
PY2022 Recipient $8,539.60 3
PY2022 Principal investigator $221,491.86 60
PY2021 Recipient $40,104.00 15
PY2021 Principal investigator $235,417.23 45
PY2020 Principal investigator $547,839.81 74
PY2019 Recipient $1,141.05 5
PY2019 Principal investigator $378,637.76 82

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $600.00 12/31/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Phase 4 (PMR Pediatric GAD) SCT-MD-60 No dispute reported 06/30/2026 721318079
Principal investigator 1 Allergan, Inc. $14,875.37 12/31/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721318121
Principal investigator 1 H. Lundbeck A S $1,920.00 12/17/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) No dispute reported 06/30/2026 747612961
Principal investigator 1 H. Lundbeck A S $616.80 12/17/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) No dispute reported 06/30/2026 747612963
Principal investigator 1 Adlon Therapeutics L.P. $75.00 12/16/2020 Non-covered Recipient Entity
AMR-BABAR RESEARCH INC
ADA4003 No dispute reported 06/30/2026 748841397
Principal investigator 1 Allergan, Inc. $68,494.05 12/15/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721313339
Principal investigator 1 Allergan, Inc. $3,566.90 12/10/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721311567
Principal investigator 1 Adlon Therapeutics L.P. $75.00 12/08/2020 Non-covered Recipient Entity
AMR-BABAR RESEARCH INC
ADA4003 No dispute reported 06/30/2026 748841391
Principal investigator 1 Adlon Therapeutics L.P. $13,024.80 12/01/2020 Non-covered Recipient Entity
AMR-BABAR RESEARCH INC
ADA4003 No dispute reported 06/30/2026 748841341
Principal investigator 1 Adlon Therapeutics L.P. $75.00 12/01/2020 Non-covered Recipient Entity
AMR-BABAR RESEARCH INC
ADA4003 No dispute reported 06/30/2026 748841347
Principal investigator 1 Allergan, Inc. $400.00 11/30/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721309947
Principal investigator 1 H. Lundbeck A S $9,145.17 11/24/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) No dispute reported 06/30/2026 747612805
Principal investigator 1 Allergan, Inc. $38,111.15 11/20/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721309449
Principal investigator 1 H. Lundbeck A S $10,000.00 11/19/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) No dispute reported 06/30/2026 747612707
Principal investigator 1 Allergan, Inc. $2,612.15 11/12/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721307617
Principal investigator 1 Allergan, Inc. $315.00 11/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
LVM-MD-14 (PREA/PMR/PHASE 3/DOUBLE-BLIND) No dispute reported 06/30/2026 721307129
Principal investigator 1 Allergan, Inc. $315.00 11/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
LVM-MD-14 (PREA/PMR/PHASE 3/DOUBLE-BLIND) No dispute reported 06/30/2026 721307261
Principal investigator 1 Allergan, Inc. $315.00 11/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
LVM-MD-14 (PREA/PMR/PHASE 3/DOUBLE-BLIND) No dispute reported 06/30/2026 721307365
Principal investigator 1 Allergan, Inc. $4,000.00 11/02/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721306089
Principal investigator 1 Allergan, Inc. $600.00 11/01/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721305961
Principal investigator 1 Allergan, Inc. $400.00 11/01/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721305963
Principal investigator 1 Allergan, Inc. $400.00 11/01/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721305965
Principal investigator 1 Allergan, Inc. $100.00 11/01/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721305967
Principal investigator 1 Allergan, Inc. $200.00 10/29/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721305769
Principal investigator 1 Adlon Therapeutics L.P. $75.00 10/22/2020 Non-covered Recipient Entity
AMR-BABAR RESEARCH INC
ADA4003 No dispute reported 06/30/2026 748841277
Principal investigator 1 Allergan, Inc. $8,632.70 10/22/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721305085
Principal investigator 1 Allergan, Inc. $25,459.05 10/16/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721303405
Principal investigator 1 Allergan, Inc. $1,009.74 10/07/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721301701
Principal investigator 1 Adlon Therapeutics L.P. $2,970.00 10/06/2020 Non-covered Recipient Entity
AMR-BABAR RESEARCH INC
ADA4003 No dispute reported 06/30/2026 748841231
Principal investigator 1 Allergan, Inc. $10,000.00 09/24/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721300465
Principal investigator 1 LivaNova USA, Inc. $400.00 09/23/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 711978979
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $1,409.99 09/22/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH INC
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM (IE, MAINTENANCE) EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER No dispute reported 06/30/2026 748805523
Principal investigator 1 Allergan, Inc. $24,259.20 09/18/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721298815
Principal investigator 1 Adlon Therapeutics L.P. $15,483.60 09/04/2020 Non-covered Recipient Entity
AMR-BABAR RESEARCH INC
ADA4003 No dispute reported 06/30/2026 748841215
Principal investigator 1 Allergan, Inc. $130.00 09/03/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721295299
Principal investigator 1 LivaNova USA, Inc. $11,500.00 09/03/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 711978977
Principal investigator 1 Allergan, Inc. $327.00 09/01/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
LVM-MD-14 (PREA/PMR/PHASE 3/DOUBLE-BLIND) No dispute reported 06/30/2026 721294337
Principal investigator 1 Allergan, Inc. $700.00 09/01/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
LVM-MD-14 (PREA/PMR/PHASE 3/DOUBLE-BLIND) No dispute reported 06/30/2026 721294367
Principal investigator 1 H. Lundbeck A S $168.51 08/26/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) No dispute reported 06/30/2026 747612407
Principal investigator 1 H. Lundbeck A S $495.00 08/13/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) No dispute reported 06/30/2026 747612321
Principal investigator 1 Allergan, Inc. $5,000.00 08/11/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
AN OPEN LABEL, LONG TERM-EXTENDED ACCESS PROTOCOL FOR RAPASTINEL AS ADJUNCTIVE OR MONOTHERAPY TREATMENT IN PATIENTS WITH MAYOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721289311
Principal investigator 1 Adlon Therapeutics L.P. $6,500.00 08/07/2020 Non-covered Recipient Entity
AMR-BABAR RESEARCH INC
ADA4003 No dispute reported 06/30/2026 748841211
Principal investigator 1 Allergan, Inc. $3,800.00 08/06/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721288571
Principal investigator 1 Allergan, Inc. $400.00 08/06/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721288573
Principal investigator 1 H. Lundbeck A S $73.08 07/29/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) No dispute reported 06/30/2026 747612231
Principal investigator 1 Allergan, Inc. $1,026.24 07/22/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721286107
Principal investigator 1 Allergan, Inc. $315.00 07/16/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
LVM-MD-14 (PREA/PMR/PHASE 3/DOUBLE-BLIND) No dispute reported 06/30/2026 721284515
Principal investigator 1 Allergan, Inc. $371.00 07/16/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
LVM-MD-14 (PREA/PMR/PHASE 3/DOUBLE-BLIND) No dispute reported 06/30/2026 721284523
Principal investigator 1 Allergan, Inc. $327.00 07/16/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
LVM-MD-14 (PREA/PMR/PHASE 3/DOUBLE-BLIND) No dispute reported 06/30/2026 721284827
Principal investigator 1 Allergan, Inc. $1,092.50 07/09/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721283161
Principal investigator 1 H. Lundbeck A S $247.50 06/24/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) No dispute reported 06/30/2026 747611943
Principal investigator 1 H. Lundbeck A S $3,959.02 06/24/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) No dispute reported 06/30/2026 747611951
Principal investigator 1 H. Lundbeck A S $742.50 06/18/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) No dispute reported 06/30/2026 747611807
Principal investigator 1 Allergan, Inc. $50,622.30 06/11/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721279223
Principal investigator 1 H. Lundbeck A S $17,059.85 05/21/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) No dispute reported 06/30/2026 747611583
Principal investigator 1 H. Lundbeck A S $495.00 05/21/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) No dispute reported 06/30/2026 747611587
Principal investigator 1 Allergan, Inc. $39,325.20 05/14/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721275139
Principal investigator 1 Allergan, Inc. $327.00 05/12/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
LVM-MD-14 (PREA/PMR/PHASE 3/DOUBLE-BLIND) No dispute reported 06/30/2026 721274345
Principal investigator 1 Allergan, Inc. $9,595.95 05/12/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721274613
Principal investigator 1 Allergan, Inc. $12,300.00 04/29/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INCORPORATED
PHASE 4 (PMR PEDIATRIC GAD) No dispute reported 06/30/2026 721273365
Principal investigator 1 Allergan, Inc. $9,000.00 04/22/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721272069
Principal investigator 1 Allergan, Inc. $2,000.00 04/22/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721272071
Principal investigator 1 Allergan, Inc. $2,000.00 04/22/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721272073
Principal investigator 1 Allergan, Inc. $13,015.95 04/15/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721270543
Principal investigator 1 Allergan, Inc. $169.00 04/09/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM-EXTENDED ACCESS PROTOCOL FOR RAPASTINEL AS ADJUNCTIVE OR MONOTHERAPY TREATMENT IN PATIENTS WITH MAYOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721269257
Principal investigator 1 H. Lundbeck A S $2,226.00 03/26/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) No dispute reported 06/30/2026 747611221
Principal investigator 1 Allergan, Inc. $26,074.65 03/16/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721264573
Principal investigator 1 Allergan, Inc. $327.00 03/12/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM-EXTENDED ACCESS PROTOCOL FOR RAPASTINEL AS ADJUNCTIVE OR MONOTHERAPY TREATMENT IN PATIENTS WITH MAYOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721263335
Principal investigator 1 H. Lundbeck A S $168.51 02/25/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) No dispute reported 06/30/2026 747610961
Principal investigator 1 Allergan, Inc. $385.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721252509
Principal investigator 1 Allergan, Inc. $5,841.55 01/17/2020 Non-covered Recipient Entity
AMR BABER RESEARCH INC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721248525
Principal investigator 1 H. Lundbeck A S $2,226.00 01/17/2020 Non-covered Recipient Entity
AMR - BABER RESEARCH
Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) No dispute reported 06/30/2026 747610607
Principal investigator 1 Neurocrine Biosciences, Inc. $32,396.50 01/16/2020 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF NBI-98854 FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 749845349
Principal investigator 1 Neurocrine Biosciences, Inc. $25,174.33 01/03/2020 Non-covered Recipient Entity
AMR-BABER RESEARCH INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME No dispute reported 06/30/2026 749845275